APOBEC3G complexes decrease human immunodeficiency virus type 1 production

Journal of Virology

Volumn 85, Issue 18, 2011, Pages 9314-9326

  Martin, Kenneth L ^a   Johnson, Megan ^a   D'Aquila, Richard T ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CD63 ANTIGEN; GAG PROTEIN; MESSENGER RNA; PROTEIN P54; VIF PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; ENDOSOME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; ULTRACENTRIFUGATION; VIRION; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS REPLICATION;

CELL LINE; CYTIDINE DEAMINASE; EPITHELIAL CELLS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; MUTANT PROTEINS; T-LYMPHOCYTES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052451503     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00273-11     Document Type: Article

References (58)

1. Abudu, A., et al. 2006. Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr. Biol. 16:1565-1570.
2. Anderson, P., and N. Kedersha. 2008. Stress granules: the Tao of RNA triage. Trends Biochem. Sci. 33:141-150.
3. Bogerd, H. P., B. P. Doehle, H. L. Wiegand, and B. R. Cullen. 2004. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U. S. A. 101:3770-3774.
4. Bogerd, H. P., H. L. Wiegand, B. P. Doehle, and B. R. Cullen. 2007. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364:486-493.
5. Burnett, A., and P. Spearman. 2007. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81:5000-5013.
6. Chable-Bessia, C., et al. 2009. Suppression of HIV-1 replication by microRNA effectors. Retrovirology 6:26.
7. Chiu, Y. L., and W. C. Greene. 2008. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26:317-353.
8. Chiu, Y. L., et al. 2006. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103:15588-15593.
9. Dang, Y., X. Wang, W. J. Esselman, and Y. H. Zheng. 2006. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80:10522-10533.
10. Derdowski, A., L. Ding, and P. Spearman. 2004. A novel fluorescence resonance energy transfer assay demonstrates that the human immunodeficiency virus type 1 Pr55Gag I domain mediates Gag-Gag interactions. J. Virol. 78:1230-1242.
11. Donahue, J. P., M. L. Vetter, N. A. Mukhtar, and R. T. D'Aquila. 2008. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 377:49-53.
12. Dutko, J. A., A. E. Kenny, E. R. Gamache, and M. J. Curcio. 2010. 5' to 3' mRNA decay factors colocalize with Ty1 gag and human APOBEC3G and promote Ty1 retrotransposition. J. Virol. 84:5052-5066.
13. Fitzpatrick, K., et al. 2010. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog. 6:e1000701.
14. Gallois-Montbrun, S., et al. 2008. Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J. Virol. 82:5636-5642.
15. Gallois-Montbrun, S., et al. 2007. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81:2165-2178.
16. Goffinet, C., S. Schmidt, C. Kern, L. Oberbremer, and O. T. Keppler. 2010. Endogenous CD317/tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J. Virol. 84:11374-11384.
17. Groom, H. C., M. W. Yap, R. P. Galao, S. J. Neil, and K. N. Bishop. 2010. Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc. Natl. Acad. Sci. U. S. A. 107:5166-5171.
18. Hulme, A. E., H. P. Bogerd, B. R. Cullen, and J. V. Moran. 2007. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390:199-205.
19. Huthoff, H., and M. H. Malim. 2007. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81:3807-3815.
20. Jin, X., et al. 2005. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 79:11513-11516.
21. Kedersha, N., et al. 2005. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J. Cell Biol. 169:871-884.
22. Khan, M. A., et al. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79:5870-5874.
23. Kozak, S. L., M. Marin, K. M. Rose, C. Bystrom, and D. Kabat. 2006. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281:29105-29119.
24. Kulkarni, M., S. Ozgur, and G. Stoecklin. 2010. On track with P-bodies. Biochem. Soc. Trans. 38:242-251.
25. Kuroishi, A., K. Bozek, T. Shioda, and E. E. Nakayama. 2010. A single amino acid substitution of the human immunodeficiency virus type 1 capsid protein affects viral sensitivity to TRIM5 alpha. Retrovirology 7:58.
26. Lian, S., et al. 2007. Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. Mol. Biol. Cell 18:3375-3387.
27. Liddament, M. T., W. L. Brown, A. J. Schumacher, and R. S. Harris. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391.
28. Low, A., C. M. Okeoma, N. Lovsin, M. de las Heras, T. H. Taylor, B. M. Peterlin, S. R. Ross, and H. Fan. 2009. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385:455-463.
29. Luo, K., et al. 2007. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81:7238-7248.
30. Marin, M., S. Golem, K. M. Rose, S. L. Kozak, and D. Kabat. 2008. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J. Virol. 82:987-998.
31. Mehle, A., et al. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
32. Moser, J. J., and M. J. Fritzler. 2010. Cytoplasmic ribonucleoprotein (RNP) bodies and their relationship to GW/P bodies. Int. J. Biochem. Cell Biol. 42:828-843.
33. Nathans, R., et al. 2009. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol. Cell 34:696-709.
34. Niewiadomska, A. M., and X. F. Yu. 2009. Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr. Top. Microbiol. Immunol. 339:1-25.
35. Okeoma, C. M., J. Petersen, and S. R. Ross. 2009. Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J. Virol. 83:3029-3038.
36. Opi, S., et al. 2007. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81:8236-8246.
37. Opi, S., et al. 2006. Monomeric APOBEC3G is catalytically active and has antiviral activity. J. Virol. 80:4673-4682.
38. Pace, C., et al. 2006. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80:9259-9269.
39. Pion, M., et al. 2006. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J. Exp. Med. 203:2887-2893.
40. Reed, S. E., E. M. Staley, J. P. Mayginnes, D. J. Pintel, and G. E. Tullis. 2006. Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J. Virol. Methods 138:85-98.
41. Refsland, E. W., et al. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284.
42. Schrofelbauer, B., D. Chen, and N. R. Landau. 2004. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U. S. A. 101:3927-3932.
43. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
44. Simon, V., et al. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6.
45. Thomas, M. G., M. Loschi, M. A. Desbats, and G. L. Boccaccio. 2011. RNA granules: the good, the bad and the ugly. Cell. Signal. 23:324-334.
46. Varthakavi, V., R. M. Smith, S. P. Bour, K. Strebel, and P. Spearman. 2003. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. U. S. A. 100:15154-15159.
47. Varthakavi, V., et al. 2006. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7:298-307.
48. Vetter, M. L., and R. T. D'Aquila. 2009. Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells. J. Virol. 83:8646-8654.
49. + T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathog. 5:e1000292.
50. Wasserman, T., et al. 2010. A novel c-Jun N-terminal kinase (JNK)-binding protein WDR62 is recruited to stress granules and mediates a nonclassical JNK activation. Mol. Biol. Cell 21:117-130.
51. Wehrly, K., and B. Chesebro. 1997. p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods 12:288-293.
52. Wichroski, M. J., K. Ichiyama, and T. M. Rana. 2005. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280:8387-8396.
53. Xu, H., et al. 2004. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factorinduced depletion. Proc. Natl. Acad. Sci. U. S. A. 101:5652-5657.
54. Yu, Y., Z. Xiao, E. S. Ehrlich, X. Yu, and X. F. Yu. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872.
55. Zeitelhofer, M., P. Macchi, and R. Dahm. 2008. Perplexing bodies: the putative roles of P-bodies in neurons. RNA Biol. 5:244-248.
56. Zennou, V., D. Perez-Caballero, H. Gottlinger, and P. D. Bieniasz. 2004. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78:12058-12061.
57. Zheng, Y. H., et al. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78:6073-6076.
58. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:871-875.